Connection
Jennifer Trujillo to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Jennifer Trujillo has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.387 |
|
|
|
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
Score: 0.203
-
Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Ann Pharmacother. 2018 12; 52(12):1224-1232.
Score: 0.151
-
Nuffer W, Trujillo JM, Megyeri J. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Ann Pharmacother. 2016 May; 50(5):376-88.
Score: 0.032